<title>
PD-1 inhibitor becomes "breakthrough therapy".
</title>

<text>

<abstract>
Merck's lambrolizumab (MK-3475) monoclonal antibody received "Breakthrough Therapy" designation from the U.S. Food and Drug Administration in April for treating patients with advanced melanoma. The designation is one of many signs of progress in attacking cancer with agents designed for immune checkpoint blockade.
</abstract>

</text>
